(NASDAQ: CSTL) Castle Biosciences's forecast annual revenue growth rate of 7.67% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.92%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.72%.
Castle Biosciences's revenue in 2026 is $357,278,000.On average, 11 Wall Street analysts forecast CSTL's revenue for 2026 to be $11,119,104,063, with the lowest CSTL revenue forecast at $10,484,590,802, and the highest CSTL revenue forecast at $11,996,791,399. On average, 11 Wall Street analysts forecast CSTL's revenue for 2027 to be $12,340,167,858, with the lowest CSTL revenue forecast at $11,505,249,831, and the highest CSTL revenue forecast at $13,376,101,640.
In 2028, CSTL is forecast to generate $13,643,104,331 in revenue, with the lowest revenue forecast at $12,150,760,914 and the highest revenue forecast at $14,742,581,088.